Clinical Testing Study in Peripheral Arterial Disease

Peripheral Arterial Disease Clinical Trial

— CTS-PAD  

Official title:

Clinical Testing Study in Peripheral Arterial Disease (CTS-PAD)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05243992
• Other study ID #: CTS-PAD 0133633 Ver00004.5
• Status: Not yet recruiting
• Start date: March 2022
• Est. completion date: December 2022

Study information

• Verified date: February 2022
• Source: Perfusio Corp.
• Contact: Thomas B Ferguson, MD
• Phone: 5044739511
• Email: bruce.ferguson[@]perfusio.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The Purpose of the Clinical Testing Study in Peripheral Arterial Disease (CTS-PAD) study is to compare measurement outcomes between conventional Ankle-Brachial Index test for Peripheral Arterial Disease with a new imaging technology from which the same data can be derived, in a series of patients referred to Vascular Surgery Clinics at the University of Rochester for suspected peripheral arterial disease.

Description:

Peripheral arterial disease (PAD) is a subset of peripheral vascular disease, which describes a spectrum of perfusion- and metabolism-related threats to the tissues of the lower extremities. PAD affects an estimated 8.5 million adults in the US and > 200 million adults worldwide. PAD is atherosclerosis in the lower limbs, and classically results in inadequate oxygen supply to lower extremity musculature during walking. However, PAD is often asymptomatic, or symptoms are atypical. Risk factors are similar to cardiovascular and cerebrovascular diseases: smoking, diabetes, older age, high blood pressure, and high cholesterol.

The initial diagnostic evaluation step in symptomatic patients (i.e., classic claudication) with PAD is the conventional Ankle-Brachial Index (cABI) test. In symptomatic patients, an ABI < 0.90 (normal range 0.91-1.3) is approximately 72% sensitive and 99% specific for angiographically significant (> 50% stenosis) PAD. However, co-morbid diseases and asymptomatic/atypical patient characteristics adversely impact this test performance. In diabetics, this sensitivity falls to < 50%. Therefore, adequate strategies for screening asymptomatic/atypical patients presenting for PAD evaluation is an unmet healthcare need.

This Small Business Technology Transfer (STTR) Phase II observational study (CTS-PAD) objective is to test a novel technologic solution to address this need. Since cABI is a single factor test (< 0.9 = > 50% stenosis), it must be broadened to collect additional data that will increase the test specificity in this PAD sub-population. In parallel to stable ischemic heart disease and the importance of functional stenoses and myocardial microperfusion, these additional data should address end-organ tissue physiology as perfused by the atherosclerotic arterial supply. The asymptomatic patients' co-morbidities affect the tissue microvascularity (i.e., diabetes), and oxygen delivery and perfusion (i.e., smoking).

Perfusio Corp.'s Multi-spectral Physiologic Visualization (MSPV) imaging technology, now FDA-approved, is the base platform for this new approach, which in addition to dynamic perfusion analytics incorporates peripheral oxygen saturation (SpO2) and cardiovascular Vital Signs of Heart Rate (HR) and Blood Pressure (BP), all in immediate real-time. This CTS-PAD observational study device is non-invasive and non-contact.

The Hypothesis of the study is that ABI-type blood pressure ratio data and these tissue- and perfusion-related factors can be captured and integrated in real-time, to improve the sensitivity of evaluation in this PAD subset. The Objective of the CTS-PAD study is to document clinical Proof of Concept for this novel approach and device.

The CTS-PAD study is designed to simply collect these data for off-line, post-hoc analyses. The data from the CTS-PAD device will not be used for any clinical decision-making, and as such the clinical team will be blinded from the CTS-PAD device results data.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: December 2022
• Est. primary completion date: September 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• patients who meet the clinical, symptomatic and or the disease complexity criteria for cABI testing

• age > 21 years

• intact bilateral upper and lower extremities

Exclusion Criteria:

• patients who are not considered candidates for the cABI test

• patients < 21 years

• women who might be pregnant or who are pregnant

• patients who are not considered eligible by the Attending Vascular Surgical team in clinic for medical reasons

• patients who are unable to undergo the cABI study

• patients who are unable to complete the precedent cABI study

• patients without intact bilateral upper and lower extremities

• patients with lower extremity edema or associated vascular disease where performance of the precedent cABI test would be difficult or unlikely to yield reliable data

• asymptomatic patients without complex disease characteristics, since they would not be referred for cABI testing

Related Conditions & MeSH terms

• Peripheral Arterial Disease
• Peripheral Vascular Diseases

Intervention

Other:
• CTS-PAD device imaging
Participants in the CTS-PAD Study will undergo a conventional ABI (cABI) evaluation, followed by the non-contact imaging evaluation with the CTS-PAD device. The supplemental CTS-PAD testing will add approximately ten (10) minutes to the overall evaluation time.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Perfusio Corp.	University of Rochester

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ratio Comparison	Comparison of the cABI systolic BP threshold ratio vs. the CTS-PAD perfusion ratio	ten (10) minutes
Secondary	Clinical status impact on CTS-PAD outcomes	correlate clinical status with CTS-PAD perfusion and physiologic data (SpO2, VS data)	ten (10) minutes
Secondary	Device use and performance	Evaluate device performance and patient and provider acceptance of this approach	ten (10) minutes

External Links

•   Sponsor Web site